Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ACSL4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ACSL4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ACSL4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ACSL4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ACSL4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ACSL4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ACSL4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ACSL4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091657 | Prostate | BPH | nucleotide biosynthetic process | 60/3107 | 254/18723 | 2.34e-03 | 1.28e-02 | 60 |
GO:00716928 | Prostate | BPH | protein localization to extracellular region | 82/3107 | 368/18723 | 2.59e-03 | 1.39e-02 | 82 |
GO:005071410 | Prostate | BPH | positive regulation of protein secretion | 36/3107 | 137/18723 | 2.64e-03 | 1.41e-02 | 36 |
GO:19012937 | Prostate | BPH | nucleoside phosphate biosynthetic process | 60/3107 | 256/18723 | 2.83e-03 | 1.49e-02 | 60 |
GO:00093069 | Prostate | BPH | protein secretion | 80/3107 | 359/18723 | 2.89e-03 | 1.52e-02 | 80 |
GO:00355929 | Prostate | BPH | establishment of protein localization to extracellular region | 80/3107 | 360/18723 | 3.13e-03 | 1.63e-02 | 80 |
GO:00507088 | Prostate | BPH | regulation of protein secretion | 62/3107 | 268/18723 | 3.35e-03 | 1.73e-02 | 62 |
GO:00469492 | Prostate | BPH | fatty-acyl-CoA biosynthetic process | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
GO:00442723 | Prostate | BPH | sulfur compound biosynthetic process | 37/3107 | 148/18723 | 5.70e-03 | 2.65e-02 | 37 |
GO:19035324 | Prostate | BPH | positive regulation of secretion by cell | 62/3107 | 282/18723 | 1.07e-02 | 4.45e-02 | 62 |
GO:00075848 | Prostate | BPH | response to nutrient | 41/3107 | 174/18723 | 1.09e-02 | 4.50e-02 | 41 |
GO:190495118 | Prostate | Tumor | positive regulation of establishment of protein localization | 106/3246 | 319/18723 | 3.13e-12 | 2.70e-10 | 106 |
GO:005122218 | Prostate | Tumor | positive regulation of protein transport | 97/3246 | 303/18723 | 2.67e-10 | 1.48e-08 | 97 |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
GO:001635814 | Prostate | Tumor | dendrite development | 72/3246 | 243/18723 | 1.44e-06 | 2.59e-05 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACSL4 | SNV | Missense_Mutation | | c.1328N>A | p.Gly443Glu | p.G443E | O60488 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
ACSL4 | SNV | Missense_Mutation | | c.313N>C | p.Glu105Gln | p.E105Q | O60488 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ACSL4 | SNV | Missense_Mutation | novel | c.4A>G | p.Lys2Glu | p.K2E | O60488 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.472) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACSL4 | SNV | Missense_Mutation | | c.2007N>G | p.Ile669Met | p.I669M | O60488 | protein_coding | tolerated(0.26) | benign(0.007) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
ACSL4 | SNV | Missense_Mutation | | c.134N>A | p.Arg45Lys | p.R45K | O60488 | protein_coding | tolerated(0.18) | benign(0.02) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ACSL4 | SNV | Missense_Mutation | | c.833C>G | p.Thr278Ser | p.T278S | O60488 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACSL4 | SNV | Missense_Mutation | | c.746N>T | p.Ser249Leu | p.S249L | O60488 | protein_coding | tolerated(0.21) | benign(0.062) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACSL4 | insertion | Frame_Shift_Ins | novel | c.1162_1163insTTTATGCCACACAGTCGGTCCTCAAAATCCTGTCACCCTGG | p.Lys388IlefsTer19 | p.K388Ifs*19 | O60488 | protein_coding | | | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ACSL4 | deletion | Frame_Shift_Del | novel | c.1500delA | p.Asp501ThrfsTer20 | p.D501Tfs*20 | O60488 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ACSL4 | SNV | Missense_Mutation | novel | c.1899N>C | p.Glu633Asp | p.E633D | O60488 | protein_coding | tolerated(0.46) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |